Bispecific antibodies (bsAbs) enable novel mechanisms of action and/or therapeutic
applications that cannot be achieved using conventional IgG-based antibodies …

The progress in human disease treatment can be greatly advanced through the
implementation of nanomedicine. This approach involves targeted and cell-specific therapy …

Monoclonal antibody (mAb)-based and/or cell-based immunotherapies provide innovative
approaches to cancer treatments. However, safety concerns over targeting normal cells …

Kidney cancers comprise about 3% of all new malignancies in the United States. Renal cell
carcinomas (RCCs) are the most common type of renal malignancy making up about 85% of …

Phagocytosis, a vital defense mechanism, involves the recognition and elimination of foreign
substances by cells. Phagocytes, such as neutrophils and macrophages, rapidly respond to …

Background The advent of immunotherapy targeting immune checkpoints has conferred
significant clinical advantages to patients with lung adenocarcinoma (LUAD); However, only …

Neuroblastoma is a pediatric cancer with significant clinical heterogeneity. Despite
extensive efforts, it is still difficult to cure children with high-risk neuroblastoma …

Primary or secondary (ie, acquired) resistance is a common occurrence in cancer patients
and is often associated with high numbers of T regulatory (T reg) cells (CD4+ CD25+ …

In the early stages of antibody drug development, it is imperative to conduct a
comprehensive assessment and enhancement of the druggability attributes of potential …

Background: Mechanism of action of intravenous immunoglobulin (IVIG) is complex, and
involves the immunoglobulin G (IgG) Fc fragment binding to Fc receptors on immune cells as …